EGFR Targeting in Hormone-Refractory Prostate Cancer: Current Appraisal and Prospects for Treatment
Open Access
- 19 July 2010
- journal article
- review article
- Published by MDPI AG in Pharmaceuticals
- Vol. 3 (7) , 2238-2247
Abstract
The incidence of prostate cancer increases with age and because of its high prevalence this disease has become a major public health concern. Despite advances in our understanding of the biological mechanisms responsible for the development of this cancer, the transition to the hormone refractory stage (HRPC) and metastatic progression pose real problems of clinical management. Currently, docetaxel chemotherapy has been shown to have a slight but significant impact on survival, though the gain in median survival is still less than three months. Research is therefore continuing to improve treatment outcomes. The progression of prostate cancer is accompanied by the overexpression of EGFR (epidermal growth factor receptor) in a very large majority of cases, suggesting that this may play a mechanistic role. Unfortunately, although preclinical findings seem to be promising for therapies targeting the EGFR in HRPC, current clinical results are disappointing. These results should however encourage us to look for different ways of using anti-EGFR agents or combining them with other targeted therapies.Keywords
This publication has 54 references indexed in Scilit:
- Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adultsCritical Reviews in Oncology/Hematology, 2010
- Therapeutic efficacy of 177Lu‐CHX‐A″‐DTPA‐hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyThe Prostate, 2008
- Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase ActivityCancer Cell, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate CancerClinical Cancer Research, 2007
- A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancerBMC Cancer, 2007
- Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancerJournal of Cancer Research and Clinical Oncology, 2007
- Key cancer cell signal transduction pathways as therapeutic targetsEuropean Journal of Cancer, 2006
- Erlotinib: a new therapeutic approach for non-small cell lung cancerExpert Opinion on Investigational Drugs, 2003
- The EGFR as a target for anticancer therapy—focus on cetuximabEuropean Journal of Cancer, 2001